
ImmunoGen (IMGN) Reports Q3 Loss, Misses Revenue Estimates
Published on October 29, 2021
ImmunoGen (IMGN) delivered earnings and revenue surprises of 5.26% and -53.15%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
